[A case of advanced gastric cancer with histological complete response after S-1 chemotherapy]. 2009

Noboru Yahara, and Hiroto Hayashi, and Takumi Furuya, and Toshihiro Saeki, and Hideto Hayashi, and Yuka Inoue, and Hideo Yanai, and Noriko Ishigaki
Department of Surgery, Kanmon Medical Center.

A 58-year-old man of unresectable gastric cancer was treated with S-1 (120 mg/body/day) after gastrojejunostomy. After 5 courses of orally administration of S-1 for 4 weeks and withdrawal for 2 weeks, partial response (PR) was obtained clinically and distal gastrectomy was performed. The histological diagnosis showed no residue of carcinoma with both HE and immunohistochemical staining. The patient has been in good health and no recurrence has occurred for about 4 years and 4 months after resection.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010094 Oxonic Acid Antagonist of urate oxidase. Oteracil
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D005743 Gastrectomy Excision of the whole (total gastrectomy) or part (subtotal gastrectomy, partial gastrectomy, gastric resection) of the stomach. (Dorland, 28th ed) Gastrectomies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas

Related Publications

Noboru Yahara, and Hiroto Hayashi, and Takumi Furuya, and Toshihiro Saeki, and Hideto Hayashi, and Yuka Inoue, and Hideo Yanai, and Noriko Ishigaki
August 2011, Gan to kagaku ryoho. Cancer & chemotherapy,
Noboru Yahara, and Hiroto Hayashi, and Takumi Furuya, and Toshihiro Saeki, and Hideto Hayashi, and Yuka Inoue, and Hideo Yanai, and Noriko Ishigaki
May 2019, Gan to kagaku ryoho. Cancer & chemotherapy,
Noboru Yahara, and Hiroto Hayashi, and Takumi Furuya, and Toshihiro Saeki, and Hideto Hayashi, and Yuka Inoue, and Hideo Yanai, and Noriko Ishigaki
November 2010, Gan to kagaku ryoho. Cancer & chemotherapy,
Noboru Yahara, and Hiroto Hayashi, and Takumi Furuya, and Toshihiro Saeki, and Hideto Hayashi, and Yuka Inoue, and Hideo Yanai, and Noriko Ishigaki
November 2016, Gan to kagaku ryoho. Cancer & chemotherapy,
Noboru Yahara, and Hiroto Hayashi, and Takumi Furuya, and Toshihiro Saeki, and Hideto Hayashi, and Yuka Inoue, and Hideo Yanai, and Noriko Ishigaki
April 2010, Gan to kagaku ryoho. Cancer & chemotherapy,
Noboru Yahara, and Hiroto Hayashi, and Takumi Furuya, and Toshihiro Saeki, and Hideto Hayashi, and Yuka Inoue, and Hideo Yanai, and Noriko Ishigaki
January 2006, Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association,
Noboru Yahara, and Hiroto Hayashi, and Takumi Furuya, and Toshihiro Saeki, and Hideto Hayashi, and Yuka Inoue, and Hideo Yanai, and Noriko Ishigaki
November 2011, Gan to kagaku ryoho. Cancer & chemotherapy,
Noboru Yahara, and Hiroto Hayashi, and Takumi Furuya, and Toshihiro Saeki, and Hideto Hayashi, and Yuka Inoue, and Hideo Yanai, and Noriko Ishigaki
March 2019, Gan to kagaku ryoho. Cancer & chemotherapy,
Noboru Yahara, and Hiroto Hayashi, and Takumi Furuya, and Toshihiro Saeki, and Hideto Hayashi, and Yuka Inoue, and Hideo Yanai, and Noriko Ishigaki
January 2018, In vivo (Athens, Greece),
Noboru Yahara, and Hiroto Hayashi, and Takumi Furuya, and Toshihiro Saeki, and Hideto Hayashi, and Yuka Inoue, and Hideo Yanai, and Noriko Ishigaki
July 2016, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!